SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 29, 2002
ANTARES PHARMA, INC.
--------------------
(Exact Name of Registrant as Specified in Charter)
Minnesota 0-20945 41-1350192
--------- ------- ----------
(State or Other (Commission (I.R.S. Employer
Jurisdiction File Number) Identification No.)
of Incorporation)
707 Eagleview Boulevard, Suite 414, Exton, PA 19341
---------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 458-6200
Not Applicable
------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
By letter dated November 29, 2002, the Listing Qualifications arm of The
Nasdaq Stock Market, Inc. notified Antares Pharma, Inc. (the "Company") that the
Company is at risk of having its common stock delisted from the Nasdaq SmallCap
Stock Market.
Specifically, for the 30 consecutive trading days prior to November 29,
2002, the price of the Company's common stock closed below the minimum $1.00 per
share requirement for continued listing under certain of Nasdaq's marketplace
rules. Accordingly, Nasdaq has provided the Company 180 calendar days, or until
May 28, 2003, to regain compliance. Importantly, this 180 calendar day grace
period applies only to the bid price deficiency. If, at anytime before May 28,
2003, the bid price of the Company's common stock closes at $1.00 per share or
more for a minimum of ten consecutive trading days, Nasdaq will provide written
notification to the Company that it complies with applicable marketplace rules.
If the Company is unable to demonstrate compliance with such rules by May 28,
2003, Nasdaq advises that it will determine whether the Company meets the
initial listing criteria under other of Nasdaq's marketplace rules. If Nasdaq
makes this determination, Nasdaq advises that it will grant the Company an
additional 180 calendar day grace period to demonstrate such compliance.
Otherwise, Nasdaq will provide notification that the Company's common stock will
be delisted. At any time, the Company may appeal Nasdaq's determination to
delist its securities.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: December 3, 2002 ANTARES PHARMA, INC.
By /s/ Roger G. Harrison
----------------------------------
Roger G. Harrison
Chief Executive Officer